Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03022032 · ClinicalTrials.gov registry record · NA
The HOPE Trial and the SMART Study
A NA study of Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT03022032 is a NA study of Gynecologic Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 102 participants, below the 763-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03022032, a NA study of Gynecologic Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with a Fitbit device. The SMART Study is a sub-study of the HOPE Trial. Both studies evaluate an almost identical intervention using a Fitbit device and smartphone app(s) with the goal of improving quality-of-life for women with gynecologic cancers.
Conditions Studied
Interventions
- OTHER Standard of Care
- DEVICE Fitbit Zip
- OTHER HOPE App
- DEVICE Fitbit Charge 2
- OTHER SMART Study Intervention
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2020-09-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03022032
The ClinicalTrials.gov registry entry for NCT03022032 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 763-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gynecologic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Standard of Care is the first listed.
NCT03022032 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03022032 about?
NCT03022032 is a clinical study titled "The HOPE Trial and the SMART Study". This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with a Fitbit device. The SMART Study is a sub-study of the HOPE Trial. Both studies evaluate an almost identical intervention using a Fitbit device and smartphone app(s) with the goal of...
What is the current status of trial NCT03022032?
This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2017-04-12. Estimated completion is 2020-09-02.
What conditions does trial NCT03022032 study?
This clinical trial studies the following conditions: Gynecologic Cancer.
What interventions are being tested in trial NCT03022032?
The interventions under investigation include: Standard of Care (OTHER), Fitbit Zip (DEVICE), HOPE App (OTHER), Fitbit Charge 2 (DEVICE), SMART Study Intervention (OTHER).
Who is sponsoring clinical trial NCT03022032?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03022032 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Activity Coaching During Pelvic Radiation Therapy
RECRUITING · NA
-
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.